Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoepitope Vaccine in Newly Diagnosed Glioblastoma
NCT02510950Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2015
- Primary completion
- Feb 2017
- Modality
- Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ITK-1 in glioblastoma (GBM), sponsored by Washington University School of Medicine. Primary endpoints: Safety and tolerability of adjuvant personalized neoantigen peptide vaccine with poly-ICLC and Feasibility of the peptide vaccine with poly-ICLC. Started Dec 2015; status: terminated.
02
Drugs
ITK-1
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02510950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510950.